论文部分内容阅读
目的:研究红景天注射液辅助化疗对非小细胞肺癌晚期患者血清血管内皮因子(VEGF)的影响。方法:选择2009年5月-2011年5月我院收治的62例非小细胞肺癌晚期患者作为研究对象,并将所有研究对象按照随机分组分为红景天组与对照组;两组患者均接受顺铂联合氟尿嘧啶化疗及其他对症营养支持治疗,治疗组在上述基础上每日辅以红景天注射液。两组患者均接受治疗1个月,比较两组患者治疗前后VEGF在肺组织的阳性表达。结果:红景天组的阳性率由原来的51.1%下降到32.5%,肿瘤直径平均减小(4.4±0.9)cm;对照组VEGF的阳性率由原来的50.8%下降到41.5%,肿瘤直径减小了(2.1±0.2)cm,对照组有2例淋巴转移患者,两组治疗前阳性率无明显差异,而治疗后对照组的VEGF阳性表达率显著高于红景天组,差异具有统计学意义(P<0.01)。结论:红景天注射液辅助化疗用于治疗非小细胞肺癌晚期具有降低血管内皮活性、保护心肌缺氧,同时辅助减小癌症病灶,降低转移率的优势,可以于临床广泛推广应用。
Objective: To study the effect of Rhodiola injection adjuvant chemotherapy on serum vascular endothelial growth factor (VEGF) in advanced non-small cell lung cancer patients. Methods: Sixty-two patients with advanced non-small cell lung cancer who were treated in our hospital from May 2009 to May 2011 were selected as research subjects and all subjects were randomly divided into Rhodiola rosea group and control group. Cisplatin combined with fluorouracil chemotherapy and other symptomatic nutritional support treatment, the treatment group on the basis of the daily supplemented Rhodiola injection. Two groups of patients were treated for 1 month, comparing the two groups of patients before and after treatment VEGF expression in the lung tissue. Results: The positive rate of Rhodiola rose from 51.1% to 32.5%, and the average tumor diameter decreased (4.4 ± 0.9) cm. The positive rate of VEGF in control group decreased from 50.8% to 41.5% (2.1 ± 0.2) cm in the control group and 2 patients in the control group. There was no significant difference in the positive rate of the two groups before treatment, but the positive rate of VEGF expression in the control group after treatment was significantly higher than that of the Rhodiola Significance (P <0.01). Conclusion: Rhodiola injection adjuvant chemotherapy for the treatment of non-small cell lung cancer with lower endothelium activity, protect myocardial hypoxia, while supporting the reduction of cancer lesions, reducing the advantages of metastasis, can be widely used in clinical practice.